D.E. Shaw & Co
GRTX

D.E. Shaw & Co’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

D.E. Shaw & Co’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,693
Closed -$90K – 5900
2022
Q1 		$90K Buy
+37,693
New +$98.2K ﹤0.01% 5016

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

D.E. Shaw & Co's GRTX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2022, closing a stake of 37,693 shares — an estimated $90K sold.

D.E. Shaw & Co first reported a position in GRTX in Q1 2022 and held it in 1 quarter. The position peaked at $90K in Q1 2022. 39 funds tracked by Wall St. Rank hold GRTX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 37,693 Galera Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $90K.
  • D.E. Shaw & Co first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's Galera Therapeutics, Inc. Common Stock position peaked at $90K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.